NEW YORK — Relay Therapeutics Inc. shares climbed more than 20% in morning trading Tuesday, reaching $17.12 as investors responded to ongoing buzz around the company's precision oncology pipeline at the American Society of Clinical Oncology annual meeting in Chicago.

The clinical-stage biotechnology company, focused on small molecule therapies for cancer and genetic diseases, has seen renewed interest in its lead candidate zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor. The stock's sharp move comes amid broader sector enthusiasm for oncology advancements showcased at the May 29-June 2 gathering.

Zovegalisib continues to generate attention following earlier data readouts demonstrating clinically meaningful progression-free survival in PIK3CA-mutated, HR /HER2- metastatic breast cancer. The program holds FDA Breakthrough Therapy designation, signaling regulatory recognition of its potential.

Clinical Progress on Zovegalisib

Updated interim results from the Phase 1/2 ReDiscover trial previously showed a median progression-free survival of 11.0 months in second-line patients treated with zovegalisib plus fulvestrant. Objective response rates reached 39% overall in patients with measurable disease, with consistent efficacy observed across kinase and non-kinase PIK3CA mutations.

These findings, initially highlighted at prior scientific meetings, underscore zovegalisib's differentiated profile compared to non-selective PI3K inhibitors, which........

© International Business Times